Suppr超能文献

前列腺切除术后挽救性放疗后疾病进展的危险因素:单机构经验的长期结果

Risk Factors for Disease Progression After Postprostatectomy Salvage Radiation: Long-term Results of a Single-institution Experience.

作者信息

Rodin Danielle, Drumm Michael, Clayman Rebecca, Buscariollo Daniela L, Galland-Girodet Sigolene, Eidelman Alec, Feldman Adam S, Dahl Douglas M, McGovern Francis J, Olumi Aria F, Niemierko Andrzej, Shipley William U, Zietman Anthony L, Efstathiou Jason A

机构信息

Department of Radiation Oncology, University of Toronto, Toronto, ON, Canada.

Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, MA.

出版信息

Clin Genitourin Cancer. 2017 Aug 3. doi: 10.1016/j.clgc.2017.07.026.

Abstract

BACKGROUND

Salvage radiotherapy (SRT) has been successfully used for recurrent prostate cancer after radical prostatectomy; however, the optimal timing of SRT remains controversial. Our objective was to identify the risk factors for disease progression after SRT, with a focus on the pre-SRT prostate-specific antigen (PSA) levels in the modern era of PSA testing.

PATIENTS AND METHODS

We performed a retrospective review of 551 consecutive patients who had undergone postradical prostatectomy SRT for recurrent prostate cancer from 2000 to 2013. The exclusion criteria were hormonal therapy before or concurrent with SRT, adjuvant RT, distant metastases, and missing data. Disease progression was defined as a repeat PSA level of ≥ 0.2 ng/mL greater than the post-SRT nadir, a continued increase in the PSA level despite SRT, initiation of systemic therapy, local recurrence, nodal failure, and/or distant metastases. Univariate and multivariable Cox regression analysis were performed to identify the predictors of disease progression. Secondarily, PSA kinetics were evaluated in the model and compared using the Akaike information criterion.

RESULTS

Of the 551 patients, 307 underwent SRT, of whom 134 experienced subsequent disease progression. The median interval to recurrence was 6.03 years (95% confidence interval, 3.74-8.36 years). On multivariable analysis, Gleason score, T stage, positive surgical margins, and pre-SRT PSA level were associated with progression; PSA kinetics did not independently predict for progression. When the pre-SRT PSA level was stratified (≤ 0.30, 0.31-0.50, 0.51-1.00, and > 1 ng/mL), incremental elevations were associated with an increased risk of disease progression.

CONCLUSION

Multiple factors predict for progression after SRT. These risk factors could help identify those who would derive the greatest benefit from additional systemic treatment. The findings of the present study also support initiation of early SRT, irrespective of the PSA kinetics.

摘要

背景

挽救性放疗(SRT)已成功应用于前列腺癌根治术后复发的患者;然而,SRT的最佳时机仍存在争议。我们的目的是确定SRT后疾病进展的危险因素,重点关注现代PSA检测时代SRT前的前列腺特异性抗原(PSA)水平。

患者与方法

我们对2000年至2013年因复发性前列腺癌接受前列腺癌根治术后SRT的551例连续患者进行了回顾性研究。排除标准为SRT前或SRT期间的激素治疗、辅助放疗、远处转移和数据缺失。疾病进展定义为重复PSA水平比SRT后最低点升高≥0.2 ng/mL、尽管进行了SRT但PSA水平持续升高、开始全身治疗、局部复发、淋巴结转移和/或远处转移。进行单因素和多因素Cox回归分析以确定疾病进展的预测因素。其次,在模型中评估PSA动力学,并使用赤池信息准则进行比较。

结果

551例患者中,307例接受了SRT,其中134例随后出现疾病进展。复发的中位间隔时间为6.03年(95%置信区间,3.74 - 8.36年)。多因素分析显示,Gleason评分、T分期、手术切缘阳性和SRT前PSA水平与疾病进展相关;PSA动力学不能独立预测疾病进展。当将SRT前PSA水平分层(≤0.30、0.31 - 0.50、0.51 - 1.00和>1 ng/mL)时,PSA水平的逐步升高与疾病进展风险增加相关。

结论

多种因素可预测SRT后的疾病进展。这些危险因素有助于识别那些将从额外的全身治疗中获得最大益处的患者。本研究结果也支持早期进行SRT,而不考虑PSA动力学情况。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验